Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma –

– Rademikibart reduced annualized exacerbations in patients with eosinophilic-driven type 2 asthma –

Read more at globenewswire.com